(A) Schematic presentation of experimental protocol. KO Treg cells were
sorted and cultured withanti-CD3andanti-CD28 plusIL-2for3days. Cells were
infected with lentivirus expressing the Thy1.1 reporter plus IL-23R-shRNA or
Ctrl-shRNA. On day 4, sorted Thy1.1+ Treg along with
CD45.1+ naive CD4+ T cells were transferred into
Tcra−/−
hosts followed by immunization with NP-OVA in CFA on day 11. Splenocytes were
analyzed on day 20.
(B) Thy1.1+ TFR, CD45.2−
Thy1.1− TFH and GL7+ B cells,
IL-17A, and IFNγ production by Thy1.1+ TFR.
(C) Frequency of CD45.2− Thy1.1−
TFH, Bcl6+ IL-17A+, and Bcl6+
IFNγ+ in donor Thy1.1+ TFR cells and
in anti-NP IgG titers.
(D–F) WT, KO,
Stat3fl/+Prdm1fl/flFoxP3Cre
(Stat3fl/+ + KO), and
Stat3fl/flPrdm1fl/flFoxP3Cre
(Stat3fl/fl + KO) mice were analyzed 10 days post-immunization
with NP-OVA in CFA.
(D) Splenic TFR, TFH, GC B cells, and
Bcl6+IL-17A+ in Treg.
(E) Frequency of TFR and Bcl6+IL-17A+
in Treg and in serum anti-NP IgG titers.
(F) FoxP3 expression in TFR by the indicated mouse
strains.
In (A)–(C), the data represent one of two experiments (C: n =
4/group). In (D)–(F), the results are pooled from two independent
experiments (E, n = 4–9/group). *p < 0.05, **p < 0.01, ***p
< 0.001, and ****p < 0.0001 (unpaired two-tailed Student’s
t test). Error bars indicate means ± SEMs.
See also Figure
S5.